Anti-Infectives · LP-021
Mebendazole Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-021Anti-Infectives
- Generic identity
- MebendazoleTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-021
- Generic identity
- Mebendazole
- Presentation
- Tablet
- Catalogue strength
- 100 mg; 500 mg
- Catalogue pack
- Blister or bottle
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: mebendazole.
- Catalogue dosage form: tablet.
- Proposed strengths: 100 mg and 500 mg.
- General pack types: blister or bottle.
Layer 02 · Unresolved product-specific fields
- Whether either strength is chewable, scored, dispersible, film-coated or another specific tablet type.
- Strength-to-pack type/count mapping and exact quantitative composition.
- Approved indication, age eligibility and administration instructions for each strength/form.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100 mg | Tablet — exact tablet type not established | — | Pack type list: blister or bottle; no strength-specific mapping supplied | Do not import chewable status from external products. |
| B | 500 mg | Tablet — exact tablet type not established | — | Pack type list: blister or bottle; no strength-specific mapping supplied | Do not import tablet type, regimen or pack count from external products. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Mebendazole is an anthelmintic used for selected intestinal worm infections. Identifying the likely parasite and reviewing the patient’s age and clinical circumstances are necessary before treatment. A medicine that treats one intestinal infestation does not automatically cover every cause of abdominal symptoms. This page offers ingredient education; it does not establish the approved indication, age range or effectiveness of a Luang Pharma tablet.
Clinical context and therapeutic role
Threadworm and other intestinal worm infections involve different diagnostic and public-health considerations. Household hygiene and prevention of reinfection can be as important as selecting a medicine. Persistent symptoms may need investigation rather than repeated treatment, especially with weight loss, anemia or travel-related exposures. A clinician or pharmacist should review pregnancy, breastfeeding, liver disease and other medicines, and establish whether the particular tablet is suitable for the person.
Selected safety context
Abdominal pain, diarrhoea and wind can occur. Serious allergic or skin reactions are uncommon but require urgent attention. Concurrent metronidazole warrants special review because serious skin reactions have been reported with the combination. Liver and blood-cell problems are additional concerns in some settings, particularly prolonged use. A young child’s ability to take the selected tablet safely must be assessed. Unexplained persistent pain, fever or blood in the stool requires medical review.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: MebendazoleArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 22 July 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-021.
Professional enquiries
Request product-specific evidence for LP-021.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.